Efficacy of eribulin in breast cancer: a short report on the emerging new data

References

• MukhtarEAdhamiVMMukhtarHTargeting microtubules by natural agents for cancer therapyMol Cancer Ther201413227528424435445
   PubMedGoogle Scholar
• CortesJO’ShaughnessyJLoeschDEribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyLancet2011377976991492321376385
   PubMed Web of Science ®Google Scholar
• TowleMJSalvatoKABudrowJIn vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin BCancer Res20016131013102111221827
   PubMed Web of Science ®Google Scholar
• DoodhiHProtaAERodríguez-GarcíaRTermination of pro-tofilament elongation by eribulin induces lattice defects that promote microtubule catastrophesCurr Biol201626131713172127321995
   PubMedGoogle Scholar
• SmithJAWilsonLAzarenkoOEribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instabilityBiochemistry20104961331133720030375
   PubMed Web of Science ®Google Scholar
• OkounevaTAzarenkoOWilsonLLittlefieldBAJordanMAInhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseMol Cancer Ther2008772003201118645010
   PubMed Web of Science ®Google Scholar
• Mc GeeMMTargeting the mitotic catastrophe signaling pathway in cancerMediators Inflamm2015201514628226491220
   PubMed Web of Science ®Google Scholar
• TowleMJSalvatoKAWelsBFEribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditionsCancer Res201171249650521127197
   PubMed Web of Science ®Google Scholar
• WilsonLLopusMMillerHPEffects of eribulin on microtubule binding and dynamic instability are strengthened in the absence of the βIII tubulin isotypeBiochemistry201554426482648926435331
   PubMedGoogle Scholar
• PoruchynskyMSKomlodi-PasztorETrostelSMicrotubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteinsProc Natl Acad Sci U S A201511251571157625605897
   PubMed Web of Science ®Google Scholar
• SmithJASlusherBSWozniakKMStructural basis for induction of peripheral neuropathy by microtubule-targeting cancer drugsCancer Res201676175115512327488522
   PubMedGoogle Scholar
• ChanezBGonçalvesABadacheAVerdier-PinardPEribulin targets a ch-TOG-dependent directed migration of cancer cellsOncotarget2015639416674167826497677
   PubMedGoogle Scholar
• YoshidaTOzawaYKimuraTEribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) statesBr J Cancer201411061497150524569463
   PubMed Web of Science ®Google Scholar
• TerashimaMSakaiKTogashiYSynergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell linesSpringerplus2014341725140293
   PubMed Web of Science ®Google Scholar
• FunahashiYOkamotoKAdachiYEribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer modelsCancer Sci2014105101334134225060424
   PubMed Web of Science ®Google Scholar
• UedaSSaekiTTakeuchiHIn vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumabBr J Cancer2016114111212121827140309
   PubMed Web of Science ®Google Scholar
• ObaTIzumiHItoKIABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell linesOncotarget2016743700117002727588398
   PubMedGoogle Scholar
• MorganRJSynoldTWLongmateJAPharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trialCancer Chemother Pharmacol201576589790726362045
   PubMed Web of Science ®Google Scholar
• DevrieseLAWitteveenPOMarchettiSPharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairmentCancer Chemother Pharmacol201270682383223010853
   PubMed Web of Science ®Google Scholar
• TanARSarantopoulosJLeeLPharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal functionCancer Chemother Pharmacol20157651051106126433580
   PubMed Web of Science ®Google Scholar
• KaufmanPAAwadaATwelvesCPhase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol201533659460125605862
   PubMed Web of Science ®Google Scholar
• VahdatLTPruittBFabianCJPhase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol200927182954296119349550
   PubMed Web of Science ®Google Scholar
• CortesJVahdatLBlumJLPhase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineJ Clin Oncol201028253922392820679609
   PubMed Web of Science ®Google Scholar
• TwelvesCCortesJVahdatLEfficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studiesBreast Cancer Res Treat2014148355356125381136
   PubMed Web of Science ®Google Scholar
• GiottaFAcitoLCandeloroGEribulin in male patients with breast cancer: the first report of clinical outcomesOncologist Epub20161014
   PubMedGoogle Scholar
• MussHCortesJVahdatLTEribulin monotherapy in patients aged 70 years and older with metastatic breast cancerOncologist201419431832724682463
   PubMed Web of Science ®Google Scholar
• ByunKDAhnSGBaikHJEribulin mesylate combined with local treatment for brain metastasis from breast cancer: two case reportsJ Breast Cancer201619221421727382400
   PubMedGoogle Scholar
• McIntyreKO’ShaughnessyJSchwartzbergLPhase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancerBreast Cancer Res Treat2014146232132824699910
   PubMedGoogle Scholar
• WilksSPuhallaSO’ShaughnessyJPhase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancerClin Breast Cancer201414640541225024001
   PubMed Web of Science ®Google Scholar
• YardleyDAReevesJDeesECRamucirumab with eribulin versus eribulin in locally recurrent or metastatic breast cancer previously treated with anthracycline and taxane therapy: a multicenter, randomized, phase II studyClin Breast Cancer2016166471479.e127569274
   PubMed Web of Science ®Google Scholar
• AbrahamJRobidouxATanARPhase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9Breast Cancer Res Treat2015152239940526126970
   PubMedGoogle Scholar
• YardleyDDyehouseKManiAAbstract P3-11-08: eribulin/cyclophosphamide (ErC) versus docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in locally advanced HER2-negative breast cancer: a randomized phase II trial of the Sarah Cannon Research InstituteCancer Res2015759 supplP3-1108
   Google Scholar
• KaklamaniVGJerussJSHughesEPhase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)Breast Cancer Res Treat2015151362963826006067
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSTauerKWHermannRCNikolinakosPGHoutsACPhase I/II study of neoadjuvant eribulin mesylate, carboplatin, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancerJ Clin Oncol20143215 suppl abstr 604
   Google Scholar
• SmithJWVukeljaSHoffmanADPhase II, multicenter, single-arm, feasibility study of eribulin combined with capecitabine for adjuvant treatment in estrogen receptor-positive, early-stage breast cancerClin Breast Cancer2016161313726433876
   PubMedGoogle Scholar
• CortesJHudgensSTwelvesCHealth-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trialBreast Cancer Res Treat2015154350952026567010
   PubMed Web of Science ®Google Scholar
• GarroneOMontemurroFSaggiaCEribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real lifeSpringerplus201655926835238
   PubMedGoogle Scholar
• Dell’OvaMDe MaioEGuiuSTumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter studyBMC Cancer20151565926449988
   PubMed Web of Science ®Google Scholar
• GamucciTMichelottiAPizzutiLEribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational studyJ Cancer20145532032724723974
   PubMed Web of Science ®Google Scholar